Celltrion of South Korea unveiled positive late-stage data showing its investigational COVID-19 antibody treatment slowed severe symptoms in over 70% of patients, including those considered high-risk due to their underlying conditions. Data from the Phase 3 trials, which involved 1,315 participants from 13 countries, showed the treatment shortened the recovery period by nearly five days.